MX2020011588A - Anticuerpos de alta afinidad a pd-1 y lag-3 y proteinas de union bispecificas preparadas a partir de las mismas. - Google Patents

Anticuerpos de alta afinidad a pd-1 y lag-3 y proteinas de union bispecificas preparadas a partir de las mismas.

Info

Publication number
MX2020011588A
MX2020011588A MX2020011588A MX2020011588A MX2020011588A MX 2020011588 A MX2020011588 A MX 2020011588A MX 2020011588 A MX2020011588 A MX 2020011588A MX 2020011588 A MX2020011588 A MX 2020011588A MX 2020011588 A MX2020011588 A MX 2020011588A
Authority
MX
Mexico
Prior art keywords
lag
binding proteins
high affinity
affinity antibodies
made therefrom
Prior art date
Application number
MX2020011588A
Other languages
English (en)
Inventor
Xuan Wu
Shiyong Gong
Chengbin Wu
Original Assignee
Shanghai Epimab Biotherapeutics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Epimab Biotherapeutics Co Ltd filed Critical Shanghai Epimab Biotherapeutics Co Ltd
Publication of MX2020011588A publication Critical patent/MX2020011588A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se describen anticuerpos de alta afinidad que reconocen el Ligando 1 de Muerte Programada (PD-1) y la proteína del Gen 3 de Activación Linfocitica (LAG-3). Los sitios de unión de los anticuerpos anti-PD-1 y anti-LAG-3 humanizados se incorporan en un formato de inmunoglobulina Fabs-en-Tandem sin pérdida significativa de afinidad de unión, y las proteínas de unión biespecíficas y multivalentes resultantes pueden unirse tanto a PD- 1 y LAG-3 simultáneamente. Tales proteínas de unión a FIT-Ig biespecíficas son útiles para el tratamiento del cáncer.
MX2020011588A 2018-05-03 2019-04-30 Anticuerpos de alta afinidad a pd-1 y lag-3 y proteinas de union bispecificas preparadas a partir de las mismas. MX2020011588A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2018085468 2018-05-03
PCT/CN2019/085164 WO2019210848A1 (en) 2018-05-03 2019-04-30 High affinity antibodies to pd-1 and lag-3 and bispecific binding proteins made therefrom

Publications (1)

Publication Number Publication Date
MX2020011588A true MX2020011588A (es) 2020-12-07

Family

ID=68386276

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020011588A MX2020011588A (es) 2018-05-03 2019-04-30 Anticuerpos de alta afinidad a pd-1 y lag-3 y proteinas de union bispecificas preparadas a partir de las mismas.

Country Status (11)

Country Link
US (1) US20210188980A1 (es)
EP (1) EP3788079A4 (es)
JP (1) JP7368453B2 (es)
KR (1) KR20210005894A (es)
CN (1) CN112074541A (es)
AU (1) AU2019263850A1 (es)
BR (1) BR112020022371A2 (es)
CA (1) CA3097916A1 (es)
MX (1) MX2020011588A (es)
TW (1) TWI784190B (es)
WO (1) WO2019210848A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2931641C (en) * 2013-12-30 2022-05-10 Epimab Biotherapeutics Inc. Fabs-in-tandem immunoglobulin and uses thereof
IL293138A (en) * 2019-11-26 2022-07-01 Shanghai Epimab Biotherapeutics Co Ltd Antibodies to cd3 and bcma and bispecific binding proteins produced from them
CN114907478A (zh) * 2021-02-08 2022-08-16 迈威(上海)生物科技股份有限公司 结合lag-3的抗体及其用途
CN117120470A (zh) * 2021-03-10 2023-11-24 北京拓界生物医药科技有限公司 Pd-1结合蛋白及其医药用途
CA3213682A1 (en) * 2021-03-31 2022-10-06 Simon Edward PLYTE Multispecific binding moieties comprising novel pd-1 binding domains
CN114989297B (zh) * 2022-06-14 2022-10-25 北京科跃中楷生物技术有限公司 包含辣根过氧化物酶标记的抗体的试剂盒
WO2024072893A1 (en) * 2022-09-28 2024-04-04 Incyte Corporation Anti-pd-1/lag-3 bispecific antibodies and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2931641C (en) 2013-12-30 2022-05-10 Epimab Biotherapeutics Inc. Fabs-in-tandem immunoglobulin and uses thereof
JOP20200094A1 (ar) * 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
US20150259420A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
JO3663B1 (ar) * 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
GB201500319D0 (en) * 2015-01-09 2015-02-25 Agency Science Tech & Res Anti-PD-L1 antibodies
TWI773646B (zh) * 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
IL297090A (en) 2015-07-30 2022-12-01 Macrogenics Inc Molecules that bind pd-1 and methods of using them
WO2017024515A1 (en) * 2015-08-11 2017-02-16 Wuxi Biologics (Cayman) Inc. Novel anti-pd-1 antibodies
CA3132021C (en) * 2015-11-18 2024-03-12 Merck Sharp & Dohme Corp. Pd1 and/or lag3 binders
WO2017132827A1 (en) * 2016-02-02 2017-08-10 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
TWI786044B (zh) * 2016-05-13 2022-12-11 美商再生元醫藥公司 藉由投予ｐｄ-１抑制劑治療皮膚癌之方法
WO2017220569A1 (en) * 2016-06-20 2017-12-28 F-Star Delta Limited Binding molecules binding pd-l1 and lag-3
CN114456269A (zh) * 2016-09-21 2022-05-10 基石药业（苏州）有限公司 一种新的pd-1单克隆抗体
RU2755503C2 (ru) 2016-10-13 2021-09-16 Симфоген А/С Анти-lag-3 антитела и их композиции

Also Published As

Publication number Publication date
JP7368453B2 (ja) 2023-10-24
TW202041537A (zh) 2020-11-16
EP3788079A4 (en) 2022-12-21
CA3097916A1 (en) 2019-11-07
BR112020022371A2 (pt) 2021-02-02
KR20210005894A (ko) 2021-01-15
WO2019210848A1 (en) 2019-11-07
US20210188980A1 (en) 2021-06-24
EP3788079A1 (en) 2021-03-10
CN112074541A (zh) 2020-12-11
TWI784190B (zh) 2022-11-21
JP2021522347A (ja) 2021-08-30
AU2019263850A1 (en) 2020-11-19

Similar Documents

Publication Publication Date Title
MX2020011588A (es) Anticuerpos de alta afinidad a pd-1 y lag-3 y proteinas de union bispecificas preparadas a partir de las mismas.
MX2022006230A (es) Anticuerpos contra cd3 y bcma, y proteinas de union biespecificas hechas a partir de estos.
MX2019012793A (es) Agentes anticuerpos dirigidos contra el gen de activación de linfocitos-3 (lag-3) y usos de los mismos.
MX2022009306A (es) Loseta de nucleo de espuma densificada (dfc) con linea de anticuerpos de dominio individual de cd28 y constructos multivalentes y multiespecíficas de los mismos.
AU2018334886A1 (en) Novel bispecific polypeptide complexes
EA201990285A1 (ru) Гетеродимерные иммуноглобулиновые конструкции и способы их получения
EP3812398A3 (en) Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
WO2016126858A3 (en) Antibodies directed against lymphocyte activation gene 3 (lag-3)
MX2022014463A (es) Construcciones de union a antigeno para moleculas diana.
MY194997A (en) Anti-ccr7 antibody drug conjugates
TN2019000294A1 (en) Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
PH12020551173A1 (en) Anti-pd-l1 antibodies and uses thereof
MX2019010392A (es) Moleculas de fusion de ectodominios receptores de tgf-b y sus usos.
WO2019060750A3 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
AU2019433019A8 (en) Antibodies binding CD40 and uses thereof
WO2019195623A3 (en) Heterodimeric antibodies that bind fibroblast activation protein
NZ761636A (en) Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods
EP4249511A3 (en) Anti-pd-l1/anti-lag3 bispecific antibodies and uses thereof
MX2023004054A (es) Anticuerpos anti-dectina 1 y metodos de uso de los mismos.
WO2020218951A3 (ru) Моноклональное антитело, которое специфически связывается с gitr
MX2023010499A (es) Anticuerpos heterodimericos que se unen a cd3 y cldn6.
MX2021006930A (es) Construcciones de proteínas de fusión para enfermedades asociadas al complemento.
ZA202206437B (en) Claudin18.2 binding moieties and uses thereof
MX2021010877A (es) Moleculas de union a cumulo de diferenciacion 3 (cd3).
CR20230245A (es) Moléculas de unión a gucy2c y sus usos